Long-term bisphosphonate treatment of bone metastases from renal cell carcinoma [2]

Journal of Clinical Oncology

Volumn 22, Issue 20, 2004, Pages 4233-4234

  Michaelson, M Dror ^a   Rosenthal, Daniel I ^a   Smith, Matthew R ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NARCOTIC ANALGESIC AGENT; PAMIDRONIC ACID; ZOLEDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; IMIDAZOLE DERIVATIVE;

AGED; ANAMNESIS; BONE METASTASIS; CASE REPORT; CLINICAL FEATURE; HUMAN; KIDNEY CARCINOMA; LETTER; LONG TERM CARE; MALE; NEPHRECTOMY; OSTEOPENIA; PATHOLOGIC FRACTURE; PRIORITY JOURNAL; BONE TUMOR; KIDNEY TUMOR; METASTASIS; PATHOLOGY;

AGED; BONE NEOPLASMS; CARCINOMA, RENAL CELL; DIPHOSPHONATES; HUMANS; IMIDAZOLES; KIDNEY NEOPLASMS; MALE;

EID: 7044253267     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.99.142     Document Type: Letter

References (3)

1. Zekri J, Ahmed N, Coleman RE, et al: The skeletal metastatic complications of renal cell carcinoma. Int J Oncol 19:379-382, 2001
2. Lipton A, Zheng M, Seaman J: Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma. Cancer 98:962-969, 2003
3. Negrier S, Escudier B, Gomez F, et al: Prognostic factors of survival and rapid progression in 782 patients with metastatic renal carcinomas treated by cytokines: A report from the Groupe Francais d'Immunotherapie. Ann Oncol 13:1460-1468, 2002